title: Vincristine-induced unilateral ptosis in a child.
abstract: Vincristine is a vinca alkaloid used in combination with other agents in the treatment of solid tumors, lymphoma, and leukemia, as well as for idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia. A dose-limiting complication of vinca alkaloids is neurotoxicity. Vincristine is the oldest and also the most neurotoxic agent in this group. Described here is the case of a 4-year-old girl with unilateral palpebral ptosis. She has been diagnosed with precursor B-cell acute lymphoblastic leukemia. Ptosis was noted on the 45th day of therapy, and the last vincristine was administered on the 28th day of protocol 1. Vincristine-induced unilateral palpebral ptosis is a novel finding. Experience with this case suggests conservative treatment, with periodic examination, especially if ptosis is mild.
authors.affiliation: Department of Pediatric Hematology, Gulhane Military Medical Academy, 06018 Etlik, Ankara, Turkey. orhangursel08@mynet.com
authors.forename: Orhan
authors.initials: O
authors.lastname: Gursel
authors.forename: Erkan
authors.initials: E
authors.lastname: Sari
authors.forename: Demet
authors.initials: D
authors.lastname: Altun
authors.forename: A Avni
authors.initials: AA
authors.lastname: Atay
authors.forename: Ridvan
authors.initials: R
authors.lastname: Akin
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D001763:Blepharoptosis / Q000139:chemically induced* / Q000473:pathology; D002675:Child, Preschool; D005260:Female; D007839:Functional Laterality; D006801:Humans; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy; D013997:Time Factors; D016896:Treatment Outcome; D014750:Vincristine / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D014750:Vincristine